MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
property and equipment
$453K
Issue of shares from
the exercise of...
$2K
Effect of exchange
rates on cash, cash...
$7,013K
Net cash provided
by/(used) in investing...
$416K
Net cash provided by
financing activities
$2K
Canceled cashflow
$37K
Net decrease in
cash, cash...
-$40,548K
Canceled cashflow
$7,431K
Research and development
incentives receivable
-$6,417K
Depreciation and
amortization
$5,845K
Impairment of long-lived
assets
$5,794K
Unrealized foreign
exchange loss
-$3,742K
Non-cash lease expenses
$3,332K
Prepaid expenses and
other current assets
-$1,704K
Share based
compensation
$468K
Non-cash interest
expense
$51K
Change in contingent
consideration
$26K
Purchases of property and
equipment
$37K
Net cash used in
operating activities
-$47,979K
Canceled cashflow
$27,379K
Net loss
-$66,458K
Accrued expenses and
other current...
-$3,793K
Accounts payable
-$2,202K
Operating lease
liabilities
-$1,979K
Deferred income
-$506K
Profit on sale of
property and equipment
$245K
Deferred tax benefit
-$175K
Back
Back
Cash Flow
source: myfinsight.com
Barinthus Biotherapeutics plc. (BRNS)
Barinthus Biotherapeutics plc. (BRNS)